| |
Is your lab informatics platform science-aware™️? Many of today's LIMS and ELNs cannot flex without tedious coding or SQL. Read our guide and discover five key markers of a modern lab platform that drives productivity and simplifies life in the lab.
|
|
Today's Big NewsApr 24, 2023 |
| By Gabrielle Masson Novartis is doling out $40 million cash for exclusive licensing rights to 3B Pharmaceuticals’ cancer-targeting tech, wrapping up some loose ends for a radiotherapy picked up from Clovis Oncology at the end of last year. |
|
|
|
By Andrea Park Two years after submitting the latest version of its insulin pump technology for FDA approval—and three years after it was first made available in Europe—Medtronic has finally secured the agency’s signoff to begin selling the MiniMed 780G system in the U.S. |
By Zoey Becker After a partial clinical hold caused bluebird to miss its own first-quarter FDA filing goal, the company says its sickle cell disease gene therapy application is in. |
By Fraiser Kansteiner Developing meds for amyotrophic lateral sclerosis (ALS) is challenging under the best of circumstances. Now, Apellis Pharmaceuticals has run into a setback for its candidate. |
|
Thursday, May 4, 2023 | 11am ET / 8am PT Join industry experts for this insightful webinar to learn more about enzyme inhibition studies. We’ll explore how these studies drive informed decisions for drug developers, frequently asked questions from sponsors, recommendations for achieving successful regulatory submission, and more. Register now.
|
|
By James Waldron U.K. biotech investment got off to a “slow start” this year, with the amount raised in the first quarter dropping 39%, according to the latest report from an industry body. |
By Andrea Park In a first-quarter earnings report released Monday, Philips clocked a net loss of 665 million euros, thanks in large part to ongoing restructuring efforts and the still-rippling effects of the June 2021 recall of 5.5 million of the company’s respiratory devices. |
By Max Bayer Mount Sinai is bolstering its regenerative medicine research with the establishment of a new institute. The Institute of Regenerative Medicine will have three related wings with the overarching goal of turning novel research into medicines. |
By Fraiser Kansteiner Eli Lilly is selling Baqsimi to California’s Amphastar for $500 million in cash upfront. Amphastar is on the hook for an additional $125 million upon the one-year anniversary of the deal’s close, expected in the third quarter. Further, Lilly is in line to receive sales-based milestones worth up to $450 million, the companies said Monday. |
By Conor Hale The deal could become one of Boston Scientific’s largest deals ever, possibly ranking in the double-digit billions, the report said. |
By Max Bayer Ionis and AstraZeneca are providing the first detailed look at phase 3 data of eplontersen, a treatment for ATTR polyneuropathy that's going toe-to-toe against Alnylam's franchise. AstraZeneca signed a collaboration deal worth up to $3.5 billion to co-develop and commercialize the drug. |
By Kevin Dunleavy As its Kenvue spinoff nears, J&J is conducting an IPO roadshow this week to drum up interest from investors, sources told The Wall Street Journal. They also said J&J hopes to raise at least $3.5 billion in the offering at a valuation of $40 billion. |
Fierce podcastsDon't miss an episode |
| This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
May 1 - 3, 2023 | Jersey City, NJ
Explore In-Depth Discussions Across 3 Tracks Dedicated to Medical Affairs Professionals. Last chance to register! Don’t miss out, register today.
|
|
| ResearchStrategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
| WhitepaperHow can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
| WhitepaperThe preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| WhitepaperWe’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| WhitepaperHow advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
